Kiniksa Pharmaceuticals International, plc (KNSA) › Cost of RevenueKiniksa Pharmaceuticals International, plc (KNSA) — Cost of RevenueAnnual figures by period end, from SEC filings.2021-12-31: $9.10M2022-12-31: $22.89M2023-12-31: $33.41M2024-12-31: $60.91M2025-12-31: $77.67M$77.67M2021-12-31Cost of Revenue (USD)2025-12-31Period endedCost of RevenueChange YoYSource filing2025-12-31$77.67M+27.5%2026-02-24From 2025-01-012024-12-31$60.91M+82.3%2026-02-24From 2024-01-012023-12-31$33.41M+45.9%2026-02-24From 2023-01-012022-12-31$22.89M+151.6%2025-02-25From 2022-01-012021-12-31$9.10M—2022-02-24From 2021-01-01Other metrics: RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsOperating Cash FlowCapital ExpendituresShares OutstandingDividends Per ShareWeighted Average Diluted SharesEPS (Basic)